

Table 6. Risk factors for neurological involvement

Patient characteristics		With neurological involvement	Without neurological involvement	P
Age group	< 3 months	4	40	<0.001
	3 – 6 months	2	5	
	6 months to 2 years	14	4	
	2-5 years	13	44	
	>5 years	7	41	
Time from onset	<12 h	11	67	<0.01
	12-24 h	8	43	
	24-72 h	8	18	
	3-7 days	13	6	
Fever	Yes	36	112	0.299
Skin rash	Yes	7	6	0.012
Hand foot and mouth disease	Yes	3	1	0.025
Herpangina	Yes	4	4	0.087
Respiratory symptoms	Yes	5	20	0.697
Admission to intensive care unit	Yes	19	4	<0.01
Mechanical ventilation	Yes	4	2	0.02
Inotropic treatment	Yes	3	1	0.025
Transaminases increase	Yes	5	29	0.183
Troponin increase	Yes	1	1	0.403
Coagulopathy	Yes	5	5	0.054
Genotype (n=69)	CVB5	2	7	<0.01
	E11	3	2	
	E18	0	6	
	E30	2	15	
	E5	2	4	
	EV-A71	15	2	
	E9	1	0	
	E6	1	1	
	CVA6	1	0	
	E7	0	3	
	E13	1	1	

LEUKOCYTOSIS AND PLEOCYTOSIS ACCORDING TO NEUROLOGICAL INVOLVEMENT

Pleocytosis (/mm3)	With neurological involvement	177.68	0.784
	Without neurological involvement	197.18	
Lymphocytes in CSF (%)	With neurological involvement	33.48	0.113
	Without neurological involvement	42.93	
Neutrophils in CSF (%)	With neurological involvement	38.58	0.231
	Without neurological involvement	46.17	
Leukocytosis (/mm3)	With neurological involvement	13837	0.038
	Without neurological involvement	12035	
Neutrophils (/mm3)	With neurological involvement	9605	0.394

	Without neurological involvement	12626	
Lymphocytes (/mm3)	With neurological involvement	5633	0.136
	Without neurological involvement	3098	

Leukocytosis and pleocytosis according to EV-A71 genotype or other genotypes

Pleocytosis (/mm3)	EV-A71	199.24	0.416
	Other EV	288.30	
Lymphocytes in CSF (%)	EV-A71	32.22	0.423
	Other EV	39.24	
Neutrophils in CSF (%)	EV-A71	39.95	0.676
	Other EV	43.88	
Leukocytosis (/mm3)	EV-A71	14820	0.088
	Other EV	12125	

Likelihood ratio, $p < 0.001$